These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8488954)
1. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? Standage BA; Schuman ES; Ackerman D; Gross GF; Ragsdale JW Am J Surg; 1993 May; 165(5):650-4. PubMed ID: 8488954 [TBL] [Abstract][Full Text] [Related]
2. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW J Am Soc Nephrol; 1994 Apr; 4(10):1809-13. PubMed ID: 8068879 [TBL] [Abstract][Full Text] [Related]
3. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters]. Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients. Canaud B; Polito-Bouloux C; Garred LJ; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C Am J Kidney Dis; 1990 Feb; 15(2):169-75. PubMed ID: 2301388 [TBL] [Abstract][Full Text] [Related]
5. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Moreno F; Aracil FJ; Pérez R; Valderrábano F Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066 [TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human erythropoietin on vascular access. Dy GR; Bloom EJ; Ijelu GK; Merritts GW; Kramer MS; Raja RM ASAIO Trans; 1991; 37(3):M274-5. PubMed ID: 1751146 [TBL] [Abstract][Full Text] [Related]
7. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA; BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687 [TBL] [Abstract][Full Text] [Related]
8. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567 [TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Tobu M; Iqbal O; Fareed D; Chatha M; Hoppensteadt D; Bansal V; Fareed J Clin Appl Thromb Hemost; 2004 Jul; 10(3):225-32. PubMed ID: 15247979 [TBL] [Abstract][Full Text] [Related]
10. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin. González-Ortiz A; Correa-Rotter R; Vázquez-Rangel A; Vega-Vega O; Espinosa-Cuevas Á BMC Nephrol; 2019 Aug; 20(1):316. PubMed ID: 31412807 [TBL] [Abstract][Full Text] [Related]
11. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view]. Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189 [TBL] [Abstract][Full Text] [Related]
12. [Effect of recombinant human erythropoietin on the bone marrow picture in patients with chronic renal failure treated by hemodialysis]. Sułowicz W; Hanicki Z; Skotnicki AB; Wójcik J; Sydor A Przegl Lek; 1992; 49(3):88-90. PubMed ID: 1438902 [TBL] [Abstract][Full Text] [Related]
13. Access thrombosis, hospitalization, and hematocrit level in hemodialysis patients. Heard KA; Russell TA Nephrol Nurs J; 2000 Dec; 27(6):607-11. PubMed ID: 16649341 [TBL] [Abstract][Full Text] [Related]
14. Regulatory mechanisms of erythropoietin levels in dialysis patients. Tagawa H; Umezu M; Saito T; Yamakado M; Nagano M; Urabe A; Takaku F Nihon Jinzo Gakkai Shi; 1990 Mar; 32(3):297-303. PubMed ID: 2355666 [TBL] [Abstract][Full Text] [Related]
15. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study. Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523 [No Abstract] [Full Text] [Related]
16. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460 [TBL] [Abstract][Full Text] [Related]
17. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. Ifudu O; Feldman J; Friedman EA N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143 [TBL] [Abstract][Full Text] [Related]
18. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812 [TBL] [Abstract][Full Text] [Related]
19. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients]. Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783 [TBL] [Abstract][Full Text] [Related]